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Functional characterization of a 
novel non-coding mutation “Ghent 
+49A > G” in the iron-responsive 
element of L-ferritin causing 
hereditary hyperferritinaemia-
cataract syndrome
Stijn Van de Sompele  1, Lucie Pécheux2, Jorge Couso  3,4, Audrey Meunier5, Mayka Sanchez  3,4 
& Elfride De Baere  1
Hereditary hyperferritinaemia-cataract syndrome (HHCS) is a rare disorder usually caused by 
heterozygous mutations in the iron-responsive element (IRE) in the 5′ untranslated region (5′UTR) 
of the L-ferritin gene (FTL), disturbing the binding of iron regulatory proteins (IRPs) and the post-
transcriptional regulation of ferritin expression. Here, the proband of a consanguineous family 
displayed moderate bilateral cataracts and elevated serum ferritin in the absence of iron overload. 
The parents and siblings showed variable degrees of mild bilateral cataracts combined with elevated 
levels of circulating ferritin. Sequencing of FTL identified a novel 5′UTR mutation c.-151A > G, also 
named “Ghent +49A > G”. The zygosity of the mutation, occurring in homozygous and heterozygous 
state in the proband and other affected family members respectively, correlated well with severity 
of ophthalmological and hematological manifestations. The substitution is expected to impair the 
secondary structure of the upper IRE stem. Functional characterization of +49A > G by electrophoretic 
mobility shift assays demonstrated a reduced binding affinity for IRP1 compared to the wild-type IRE of 
FTL. Overall, we have expanded the repertoire of deleterious biallelic FTL IRE mutations in HHCS with 
this novel +49A > G mutation, the zygosity of which correlated well with the disease expression.
Hereditary hyperferritinaemia-cataract syndrome (HHCS) (OMIM 600886) is a rare autosomal dominant disease 
(estimated prevalence of 1 in 200,000), characterized by the combination of elevated serum ferritin in the absence 
of iron overload or other hematological abnormalities and progressive cataracts of a highly distinctive morphol-
ogy1. The genetic disorder was first described in 1995 by two independent groups2,3. HHCS might be misdiag-
nosed as hereditary hemochromatosis, since serum ferritin levels are still widely used to identify hereditary and 
acquired iron overload conditions4. As a consequence, patients with HHCS could undergo inadequate follow-up 
with repeated exams in search of iron overload or even an inappropriate phlebotomy treatment that leads to iron 
deficiency anemia, stressing the importance of a correct clinical diagnosis of HHCS3.
Patients with HHCS present a disease-causing mutation in the FTL gene, located on chromosome 19 (19q13.1). 
The FTL gene encodes the light subunit, L-ferritin (19 kDa), that together with the heavy subunit, H-ferritin 
(21 kDa, encoded by the FTH gene located on chromosome 11q12.3) constitutes the 24-subunit heteropolymer 
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ferritin protein5. Ferritin is an ubiquitously expressed protein responsible for the storage and intracellular distri-
bution of iron. The expression of the ferritin subunits is modulated by intracellular iron levels through a tightly 
regulated negative feedback system based on the interaction between cytoplasmic iron-sensing mRNA-binding 
proteins, the iron regulatory proteins (IRP1 and IRP2), and a non-coding cis-acting stem-loop structure located 
in the 5′ untranslated region (5′UTR) of both L- and H-ferritin mRNA, the iron-responsive elements (IREs)6. 
These IREs comprise four important structural parts: the hexanucleotide apical loop, the upper and lower stem 
consisting of palindromic sequences and the cytosine bulge, an unpaired cytosine residue (C-bulge) located in 
between the upper and lower stem7. In conditions of low intracellular iron levels, the high affinity IRP/IRE bind-
ing prevents the recruitment of the small ribosomal subunit to the mRNA. As a consequence, the synthesis of the 
ferritin subunits is repressed at the translational level which limits the storage and utilization of cytoplasmic iron. 
Conversely, when intracellular iron levels increase the IRP/IRE binding affinity decreases due to conformational 
changes of IRP1 and the proteasomal degradation of IRP2, resulting in the initiation of ferritin mRNA translation 
and the consequent upregulation of ferritin synthesis8,9.
Heterozygous mutations in the IRE of FTL mRNA disturbing cellular iron homeostasis are characteristic of 
HHCS. FTL IRE mutations reduce the IRP/IRE binding affinity due to changes in the IRE secondary structure 
and/or the stability of the IRE10, abrogating the IRP/IRE interaction and leading to uncontrolled translation of 
FTL mRNA, independent of the iron status. The constitutive overproduction of L-ferritin gives rise to L-subunit 
rich ferritin heteropolymers and ferritin homopolymers of 24 L-subunits, resulting in both hyperferritinaemia 
and intracellular ferritin accumulation11. Although ferritin accumulates in all cell types of HHCS patients, it turns 
out to be toxic only in the crystallin-containing lens fiber cells. There, crystalline L-ferritin deposits can be found, 
which may affect the solubility of other lens proteins or induce oxidative lens damage, altogether leading to the 
formation of cataracts12.
Here, our aim was to molecularly explain the variable expressivity of hyperferritinaemia and bilateral cataracts 
in different members of a consanguineous family with HHCS, and to functionally characterize a novel mutation 
in the 5′UTR of FTL.
Methods
Clinical assessment of patients. A Belgian family of Moroccan descent with parental consanguinity (sec-
ond cousins) (Fig. 1A) underwent hematological and ophthalmological assessment following a clinical diagnosis 
of HHCS in the 8-year-old proband (II:2). In particular, slit-lamp biomicroscopy and the measurement of iron 
parameters were performed. Normal serum ferritin levels are ranging from 12 to 300 µg/L for males and from 12 
to 150 µg/L for females13. An extended pedigree, illustrating the consanguineous relationship in this family, can 
be found in Supplementary Figure 1.
FTL analysis. The proband (II:2), the parents (I:1, I:2) and two siblings (II:1, II:3) were referred to the Center 
for Medical Genetics in the Ghent University Hospital for genetic testing of the FTL 5′UTR. An informed consent 
was obtained from all subjects or their legal representative. Genomic DNA was extracted from peripheral blood 
using the QIAamp DNA blood mini kit, according to manufacturer’s instructions (Qiagen). In our standard 
workflow the coding regions, exon-intron boundaries and UTRs of the FTL gene (NM_000146.3) were PCR 
amplified starting with 40 ng of genomic DNA using four primer pairs (Supplementary Table 1). Purification 
of the PCR products by Exonuclease I and Antarctic Phosphatase (New England Biolabs) treatment was fol-
lowed by bi-directional Sanger sequencing using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied 
Biosystems). Sequencing products were purified by CleanDTR magnetic beads (GC Biotech) and analyzed on 
a ABI PRISM 3730XL Sequencer (Applied Biosystems). Data-analysis and variant calling was performed with 
the SeqScape Software (Applied Biosystems). Given the clinical diagnosis of HHCS, data analysis was confined 
to the 5′UTR of FTL. Variants were designated according to the HGVS nomenclature and the classical nomen-
clature used for HHCS variants. Variant classification was performed following the American College of Medical 
Genetics (ACMG) guidelines of 201514. The study was conducted in accordance with the tenets of Helsinki and 
was approved by the Ghent University Hospital Ethics Committee (approval 2004/094).
Confirmation of homozygosity.  To exclude false homozygosity of the 5′UTR mutation in the proband 
due to an FTL deletion in trans with the mutation, three qPCR primer pairs were used, located in the FTL 5′UTR 
region (Supplementary Table 1). Copy number analysis was performed on the LightCycler 480 real-time PCR 
instrument (Roche) using the SYBR Green Master Mix (Roche) and 20 ng of genomic DNA of each patient and 
three positive controls15. Each reaction was run in duplicate. Data analysis was executed using the qBase+ soft-
ware (Biogazelle) and results were normalized to two reference assays (ZNF80, GPR15).
Genome-wide SNP genotyping and homozygosity mapping. In order to assess the size of the auto-
zygous region and haplotype in which the homozygous FTL 5′UTR mutation is located, genome-wide SNP gen-
otyping was performed using the HumanCytoSNP-12 BeadChip platform (Illumina). Plink software, integrated 
in ViVar, identified homozygous regions >1 Mb which were ranked according to their length and the number of 
SNPs, as described16.
FTL RNA fold predictions.  RNA folding analysis to predict the IRE structure of wild-type (WT) and 
mutated FTL was carried out using Mfold (http://unafold.rna.albany.edu/)17 and Sfold web server (http://sfold.
wadsworth.org/)18. RNA sequences used for fold predictions are shown in Supplementary Table 2.
Plasmid construction. Plasmids for generating RNA probes for electrophoretic mobility shift assay (EMSA) 
experiments were constructed based on the I-12.CAT plasmid19 using annealed synthetic complementary oli-
gonucleotides corresponding to the sequence of interest. Constructs were made for the FLT 5′ IRE +49A > G 
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mutation as well as the WT sequence (FTL 5′ IRE WT, negative control) and a mutant version bearing a C dele-
tion in the apical loop (FTL 5′ IRE +39∆C, positive control), not interacting with IRP120. After ligation using the 
Quick Ligation kit (New England Biolabs), 2 µL of the ligation product was heat-shock transformed into 50 µL 
competent TOP10 bacterial cells (Invitrogen) which were plated on LB plates containing 100 µg/mL ampicillin. 
Colonies were picked and grown in LB broth. Plasmid DNA was isolated using the Nucleospin plasmid mini 
DNA purification kit (Macherey-Nagel). Sanger sequencing was performed (GATC Biotech, Konstanz) to verify 
the presence of the correct insert in each construct. All oligonucleotides used for cloning purposes are listed in 
Supplementary Table 3. Plasmids were linearized and used as template for T7 in vitro transcription (MEGAscript 
T7 kit, Life Technologies).
EMSA experiments.  Two types of EMSA experiments were performed in this study: direct and competitive 
EMSA. For direct EMSA experiments, fluorescent-labeled probes corresponding to FTL 5′ IRE WT, +39∆C and 
+49A > G were incubated with the recombinant IRP1 protein19 in order to qualitatively assess IRP1/IRE binding. 
For competitive EMSA experiments, the fluorescent-labeled WT probe was incubated with recombinant IRP1 
together with increasing amounts of non-labeled competitor FTL 5′ IRE WT, +39∆C and +49A > G probes. 
The extent to which the non-labeled probes competed with the labeled WT probe for binding the IRP1 protein, 
provided a quantitative insight into IRP1/IRE binding affinity.
The T7 in vitro transcription reaction for the labeled probes was performed in 1X transcription buffer, 0.33 mM 
rATP, rCTP, rGTP, 3.33 µM rUTP, 20 µM ATTO-680 aminoallyl-rUTP (Jena Bioscience), 240 units T7 RNA pol-
ymerase (EMBL Heidelberg core facility), 60 units RNasin Ribonuclease Inhibitor (Promega), and 30 mM DTT 
in a total reaction volume of 45 µL, using 6 µg of template DNA. After incubation for 4 h at 37 °C, template DNA 
was degraded by TURBO DNase (Ambion) treatment. The non-labeled competitors were in vitro transcribed 
using the MEGAscript T7 kit (Life Technologies) according to the manufacturer’s instructions. ATTO-680 labe-
led probes and unlabeled competitors were purified by phenol/chloroform/isoamyl alcohol extraction and used as 
probes. Prior to protein binding, 100 ng of labeled probe, and increasing molar excess (1X, 2X, 5X, 10X, 20X, 40X, 
Figure 1. Overview of the HHCS-affected family. (A) Pedigree of the family investigated in this study, with 
segregation of the Ghent +49A > G mutation. The severity of the phenotype is represented by the darkness 
of the pedigree symbol. The pedigree shows parental consanguinity between I:1 and I:2. The proband II:2 
is indicated by an arrow. (B) Slit-lamp examination of the anterior segment of the proband (II:2) displayed 
moderate central nuclear bilateral cataracts, in the absence of scattered flecks. The proband’s father (I:1) 
presented with mild bilateral central nuclear cataracts with typical distinctive peripheral spicules, while the 
mother (I:2) and siblings (II:1, II:3) demonstrated mild bilateral central nuclear cataracts with less dense 
opacities. (C) Electropherograms of Sanger sequencing of the IRE located in the 5′UTR of the FTL gene, using 
genomic DNA of patients. The arrow indicates the nucleotide change +49A > G (c.-151A > G, NM_000146.3). 
The WT sequence is displayed on top as a reference, the homozygous sequence (II:2) in the middle and the 
heterozygous sequence (I:1, I:2, II:1, II:3) at the bottom.
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80X) of unlabeled competitor probes in case of competitive EMSA, were denatured at 95 °C for 5 min, followed 
by renaturation at room temperature. Probes were then incubated with 200 ng recombinant IRP1 protein19 in 
CLB buffer (25 mM Tris/HCl pH 7.4, 40 mM KCl, 1% Triton X-100, 1X cOmplete EDTA-free protease inhibitor 
cocktail) for 15 min at room temperature. In order to displace non-specific RNA-protein interactions, 50 ng of 
sodium heparin was added to the reaction mix. After incubation for 10 min at room temperature, 2 µL of 80% 
glycerol loading buffer was added and reaction mixtures were loaded on a 5% native acrylamide (60:1 acryla-
mide:bisacrylamide) gel in 1X TBE buffer. Gels were run at 80 V at 4 °C and visualized in the 700 nm channel 
using the Odyssey Infrared Imaging System (LI-COR Biosciences), at an intensity setting of 7.0, with resolution 
set to 169 µm and focus offset to 1.0 mm. Adjustment of brightness and contrast levels was applied to the entire 
images using the ImageJ software. After applying the despeckle and background subtraction tool, absolute band 
intensities corresponding to IRP1/IRE complexes were calculated with the ImageJ software. For direct EMSA 
experiments, intensities were normalized relative to the intensity of the shifted band of WT IRE. Normalization of 
intensities of competitive EMSA experiments was done relative to the intensity of the band in lane N. Direct and 
competitive EMSA experiments were performed in quadruplicate and triplicate respectively.
Statistical analysis. The results from the direct EMSA experiments were compared using one-way analysis 
of variance (ANOVA) with a post hoc Bonferroni multiple-comparison test. Differences between groups were 
considered statistically significant for p values less than 0.05. Statistical analyses were performed with GraphPad 
Prism 5.0.
Calculation of apparent dissociation constants (KDapp). The calculation of the KDapp values was per-
formed using a previously reported method for competition assays21. The plot of bound labeled WT probe against 











with f the ratio of observed intensity relative to the intensity in the absence of competitor, KDapp the apparent 
dissociation constant for the competitor under investigation, and [C]free the concentration of the free competitor:
= − −C C H f[ ] [ ] [ ] (1 ) (2)free i i
with [C]i the initial concentration of competitor, [H]i the initial amount of labeled WT probe. The non-linear 
leastsquares best fit apparent dissociation constant was then calculated from Equation (1).
Results
Clinical findings.  The 8-year-old proband (II:2) was referred because of highly elevated serum ferritin 
(2784 µg/L) without clinical, biological or radiologic evidence of iron overload. His familial history revealed con-
sanguinity (Fig. 1A), a long follow-up for moderate hyperferritinaemia without iron overload in his mother (I:2) 
with negative genetic testing for HFE-associated hereditary hemochromatosis and early-onset of bilateral cata-
racts at age 30 in his father (I:1). Slit-lamp examination of the anterior segment of the proband (II:2) unveiled 
moderate bilateral cataracts (Fig. 1B) compatible with a clinical diagnosis of HHCS. In the proband’s parents 
(I:1, I:2) and siblings (II:1, II:3) variable degrees of mild bilateral cataracts (Fig. 1B) were observed, with elevated, 
but significantly lower levels of circulating ferritin compared to the proband (576 µg/L, 586 µg/L, 460 µg/L, and 
661 µg/L respectively), with normal levels of serum iron and transferrin saturation. The father (I:1) was also diag-
nosed with possible Fuchs’ uveitis, a condition often resulting in secondary cataract22. In this case, however, the 
cataract morphology showed a different aspect than that usually observed in Fuchs’ uveitis. The biological and 
clinical findings in this family are summarized in Table 1.
I:1 I:2 II:1 II:2 II:3 Reference values
Age/sex 38/M 35/F 13/F 8/M 6/M —
Serum ferritin (µg/L) 576 586 460 2784 661 12–300 (M), 12–200 (F)
Serum iron (µg/dL) 117 83 155 101 65 50–170
Transferrin (mg/dL) 235 325 314 280 307 200–360
Transferrin saturation (%) 36 18 39 25 15 15–50
AST (mU/mL) 18 19 19 29 33 10–34
ALT (mU/mL) 17 12 12 16 15 10–40
Cataract Mild cataracts Mild cataracts Mild cataracts Moderate cataracts Minimal cataracts —
Other Fuchs’ uveitis — — — — —
Genotype WT/+49A > G WT/+49A > G WT/+49A > G +49A > G/+49A > G WT/+49A > G WT/WT
Table 1. Hematology values of the proband (II:2), parents (I:1, I:2), and two siblings (II:1, II:3) and summary of 
their molecular findings. Values are compared with normal reference values. Abbreviations used: ALT: alanine 
aminotransferase; AST: aspartate aminotransferase; F: female; M: male; WT: wild type.
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Molecular genetic findings.  Subsequent analysis of the 5′UTR of the FTL gene encoding the FTL IRE in 
the HHCS-affected proband revealed a novel homozygous mutation c.-151A > G (NM_000146.3). In agreement 
with the traditional nomenclature for FTL IRE mutations, the alternative name for this mutation is the “Ghent 
+49A > G” mutation (relative to the transcription initiation signal). Segregation analysis showed the presence 
of the Ghent +49A > G mutation in a heterozygous state in the parents as well as in both siblings (Fig. 1C). This 
variant was not reported in the consulted public databases (1000 Genomes Project, ExAC, dbSNP, HGMD). No 
other likely pathogenic variants in the FTL gene were observed in neither the proband nor the family members.
To exclude false homozygosity of the Ghent +49A > G mutation in the proband due to a deletion in trans 
with the mutation, a qPCR analysis was performed using three amplicons neighbouring the mutation. The corre-
sponding results ruled out false homozygosity and confirmed that the Ghent +49A > G mutation in the proband 
is present on both alleles (Supplementary Figure 2). Following ACMG guidelines, this mutation was classified as 
a pathogenic mutation (class 5) (Supplementary Table 4).
Figure 2. Predicted secondary structure of WT and +49A > G mutated FTL 5′UTR IRE RNA, computed using 
the Sfold web server18. The +49A > G mutation, indicated with an arrow, is expected to influence base pairing in 
the upper stem, resulting in an impaired secondary structure of the hexanucleotide loop and loss of the cytosine 
bulge. Secondary structure modeling by the Mfold web server yields the same result. Nucleotides are numbered 
from the transcription initiation signal. Green dots represent common base pairs between the ensemble 
centroid (EC) structure diagram and the minimum free energy (MFE) structure diagram. Blue dots represent 
base pairs predicted only by the MFE structure diagram.
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Given the parental consanguinity, genome-wide SNP genotyping was performed in the proband, the par-
ents and two siblings, in order to have more insight into the size of the autozygous region and corresponding 
haplotype containing the homozygous 5′UTR mutation. Homozygosity mapping in the proband revealed seven 
homozygous regions (>1 Mb) unique to the proband, one of which contains the FTL gene. An overview over the 
regions of homozygosity can be found in Supplementary Table 5.
The Ghent +49A > G mutation is predicted to impair the IRE structure. RNA secondary structure 
modeling of WT and mutated FTL 5′ IRE sequences was performed using the Mfold and Sfold web server. Both 
folding software packages predict that the Ghent +49A > G mutation, which is located at the basis of the upper 
stem, just above the cytosine bulge, is likely to disturb the WT IRE conformation (Fig. 2). The substitution of ade-
nine by guanine at position +49 is expected to affect base pairing with uracil at position +34, inducing a broader 
rearrangement of base pairing in the upper stem, an altered secondary structure of the apical loop and loss of the 
cytosine bulge.
The Ghent +49A > G mutation shows reduced IRP1 binding.  To assess the functional effect of the 
Ghent +49A > G mutation, the relative binding of recombinant IRP1 to the mutated IRE was evaluated in vitro 
by EMSA experiments. Qualitative results obtained by direct EMSA experiments indicate a 75% decrease (mean 
of four experiments) for binding of the Ghent +49A > G mutation to IRP1, relative to the WT FTL IRE sequence 
(Fig. 3A). As expected, the positive control +39∆C mutation showed only minimal binding to IRP1, with a 
reduction of almost 95%. The full-length gel image is included in Supplementary Figure 3. One-way ANOVA 
showed that differences in the mean of intensities for the Ghent +49A > G mutation, negative and positive control 
are statistically significant (Fig. 3B). Post hoc analysis indicated that the mean of all three groups are statistically 
different from each other. The effect of the Ghent +49A > G mutation on IRP1 binding was evaluated quantita-
tively using a more stringent assay, a competitive EMSA. Using this assay, it was demonstrated that the +49A > G 
mutant competitor is less efficient in displacing the labeled probe than the WT competitor, as observed by a more 
gradual disappearance of the shifted band on the gel in the presence of increasing amounts of +49A > G mutant 
competitor when compared to the WT competitor (Fig. 4A). In particular, the competitor containing the Ghent 
+49A > G mutation starts to compete effectively at concentrations between 10- and 20-fold excess, which is 
significantly later than the negative control WT competitor that begins to show significant competition between 
2- and 5-fold excess. In contrast, the +39∆C competitor, used as a positive control, is inefficient in displacing 
the labeled probe, since the IRE containing this mutation does not show significant competition even at 80-fold 
Figure 3. Direct EMSA experiments to qualitatively evaluate the effect of the Ghent +49A > G mutation on 
IRP/IRE binding affinity. Therefore, fluorescent-labeled probes of the +49A > G mutant IRE were incubated 
with IRP1 protein and loaded on a 5% native acrylamide gel. Fluorescent-labeled probes of the WT and +39∆C 
mutant IRE were used as negative and positive controls respectively. (A) Representative gel image showing the 
intensities of the shifted IRP1/IRE complex. Lane 1 contains the labeled WT probes in absence of IRP1. Lane 
2, 3 and 4 respectively contain labeled WT, +39∆C mutant and +49A > G mutant probes in the presence of 
IRP1. (B) Band intensities of the two mutant groups were normalized relative to the intensity of the shifted band 
of WT IRE (lane 2) and presented as the mean of four experiments ± standard error of the mean. Statistical 
analysis was done by one-way ANOVA, followed by post hoc Bonferroni multiple comparison test (*p < 0.05, 
**p < 0.01, ***p < 0.001).
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excess. Full-length gel images are included in Supplementary Figure 4. A plot of the quantified band intensities in 
function of the molar excess of the competitor is given by Fig. 4B.
Quantification of the apparent dissociation constant (KDapp) of the WT and +49A > G mutant IRE using a 
single independent site model21 indicates that the WT IRE has an KDapp of 0.50 nM, while the +49A > G mutant 
IRE demonstrates a more than 5-fold lower affinity for IRP1, with an KDapp of 2.70 nM. Since the +39∆C mutant 
IRE is ineffective at binding IRP1, no single independent site model could be fitted to the values of this mutant 
IRE, therefore no KDapp could be calculated. In summary, in vitro EMSA experiments support a decreased binding 
affinity of the +49A > G mutant IRE for IRP1.
Discussion
In this study a novel mutation in the IRE of FTL, Ghent +49A > G, was found in a homozygous and heterozygous 
state in different members of a consanguineous family with HHCS. Another mutation at the same nucleotide 
position (+49A > C) has been reported once in a family with HHCS, however, no clinical data were provided23. 
So far, more than thirty point mutations and six deletions in the FTL IRE have been identified in patients with 
HHCS24,25. The Ghent +49A > G mutation adds to the repertoire of HHCS causing mutations.
The zygosity of +49A > G was found to correlate with disease expression, with the most severe phenotype 
observed in the index case harbouring the mutation in homozygous state. In particular, the serum ferritin level 
of the proband displays a roughly 5-fold increase in comparison with the heterozygous family members and 
is almost 10-fold higher than the normal reference values. Moreover, despite the young age of the proband, 
he shows the most severe clinical manifestations of cataracts among the affected individuals. Despite the fact 
that genotype-phenotype correlations between serum ferritin levels and HHCS severity are difficult to obtain, 
mainly due to age and gender variability of serum ferritin, our observation is in line with a more severe clinical 
Figure 4. Competitive EMSA experiments to quantitatively evaluate the effect of the Ghent +49A > G 
mutation on IRP/IRE binding affinity. Fluorescent-labeled probes of the WT IRE were incubated with 
IRP1 protein and increasing molar excess (1X, 2X, 5X, 10X, 20X, 40X, 80X) of unlabeled +49A > G mutant 
competitor probes. Unlabeled competitor probes of the WT and +39∆C mutant IRE were used as negative 
and positive controls respectively. Reactions were loaded on a 5% native acrylamide gel. (A) Representative 
gel images showing the intensities of the shifted IRP1/IRE complex. Lane N contains the labeled WT probe 
with IRP1 in the absence of unlabeled competitor. The following lanes contain labeled WT probe with IRP1 
and increasing amounts of WT, +39∆C mutant and +49A > G mutant competitor. (B) Band intensities of 
the WT and two mutant groups were normalized relative to the intensity of the shifted band in the absence of 
competitor (lane N) and presented on a logarithmic scale in function of the molar excess of the competitor. 
Means ± standard error of the mean of three independent experiments are shown.
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phenotype in subjects with a homozygous mutation in comparison with heterozygous patients, as reported for 
multiple other diseases26.
So far, three HHCS families with rare homozygous mutations in the IRE of FTL have been reported25,27,28. In 
a first homozygous case serum ferritin levels were more than 2-fold higher than in heterozygous patients. The 
severity of cataracts however showed no correlation with mutation dose27. For the second case, no correlation 
between the state of zygosity and the severity of the clinical phenotype was found in the two homozygous and four 
heterozygous patients25. In the third case, only the proband was investigated, so no comparison could be made 
with heterozygous cases28. As noted previously, HHCS patients with the same mutation can demonstrate pheno-
typic diversity due to other genetic or environmental factors, concomitant pathologies or age-related penetrance6. 
Indeed, serum ferritin levels show inter- and intra-individual differences since they are affected by age and sex, 
while the age of cataract onset and its severity can be influenced by differences in diet, exposure to UV light, or 
substance abuse10. There have been, for instance, reports of young children with elevated serum ferritin levels but 
without cataracts, having the same mutation as their affected relatives with cataract12. In the proband reported 
here, the early-onset cataract formation could be explained by the unusual high levels of serum ferritin, causing 
a rapid accumulation of crystalline deposits in the lens. Interestingly, it has been demonstrated that endogenous 
FTL transcription is significantly higher in the lens compared to other eye tissues, which is likely to contrib-
ute to the pathogenic levels of FTL deposits found in HHCS lenses29. Several authors have also attempted to 
establish a relationship between the severity of the clinical features and the location of the mutation in the IRE 
structure10,25,30. In general, heterozygous mutations disturbing the hexanucleotide loop or the cytosine bulge give 
rise to strongly increased serum ferritin levels and early-onset bilateral cataract, while mutations affecting the 
base pairing of the upper or lower stem generally present a more moderate phenotype. The +49A > G muta-
tion is located at the basis of the upper stem, right above the cytosine bulge. In the heterozygous patients, the 
mutation gives rise to a moderate increase of serum ferritin and mild cataract, supporting the abovementioned 
genotype-phenotype correlation.
Sanchez et al.31 performed a series of competitive EMSA experiments to determine IRP1 binding motifs in 
the IRE of H-ferritin (FTH)31. The FTH 5′ IRE probe containing the adenine to guanine change at the position 
corresponding to position +49 of the FTL 5′ IRE, showed IRP1 binding characteristics comparable to those of 
the WT probe. This implies that this change in FTH causes no loss of IRP1 binding affinity, as opposed to the 
+49A > G mutation in FTL, shown to effectively reduce IRP1 binding. This difference could be explained by 
the hypothesis the authors derived from additional experiments. Specifically, it was shown that the presence of 
three or more G-U or U-G wobble base pairs in the FTH 5′ IRE motif severely impairs its ability to compete with 
the WT probe. The WT FTL 5′ IRE has two U-G base pairs, compared to only one in the WT FTH 5′ IRE. Since 
+49A > G induces an additional U-G base pair, the threshold of three U-G base pairs is exceeded in mutant FLT, 
but not in mutant FTH. The results of the EMSA experiments in our study therefore illustrate that the hypothesis, 
allowing a maximum of two G-U or U-G wobble base pairs in order to preserve proper binding characteristics, 
can be broadened from FTH to FTL.
Bioinformatics tools show that the substitution of adenine by guanine at position +49 in the upper stem of 
the IRE is predicted to change the secondary structure of the FTL IRE, thereby affecting the apical loop as well 
as causing a loss of the cytosine bulge, elements that are critical for IRP/IRE recognition9. Furthermore, previous 
studies suggest that proper base pairings at the basis (+34/+49) and the top (+38/+45) of the upper stem of the 
IRE are crucial for obtaining the correct arrangement of nucleotides composing the upper stem and hexanucle-
otide apical loop31.
The functional effect of the +49A > G mutation in the FTL IRE on IRP1 binding affinity was evaluated by 
means of EMSA experiments. The direct as well as competitive EMSA experiments show that +49A > G reduces, 
but not completely abolishes, the binding with recombinant IRP1. From the EMSA data, we have calculated KDapp 
values for the WT and +49A > G IRE. The KDapp value of the mutant IRE is more than 5-fold lower than WT IRE, 
which also corresponds with the outcome of the direct EMSA experiment. The observations from both types of 
EMSA experiments thus suggest that the FTL 5′ IRE with +49 A > G is capable of binding IRP1 in vitro, albeit 
with a significantly reduced binding affinity. It seems, however, that the manifestation of the HHCS phenotype is 
independent of the strength of the mutation in terms of reduction of binding affinity. In particular, mutations that 
only mildly impair IRP/IRE binding in vitro, can also induce biochemical and clinical symptoms10,25, illustrating 
the high sensitivity of the IRP/IRE complex to minor perturbations in affinity.
In conclusion, we identified a novel non-coding mutation,“Ghent +49A > G”, in the IRE of FTL causing vari-
able degrees of HHCS in a consanguineous family. The zygosity of the mutation correlated with the severity of the 
phenotypes in this family. The mutation was predicted to disrupt the secondary structure of the IRE. Functional 
characterization of the mutation revealed that +49A > G reduces, but does not completely abolishes, the binding 
to IRP1.
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